| Total (n = 336) | 3D-CRT (n = 186) | IMRT (n = 150) | P* |
---|---|---|---|---|
Age, years, median (range) | 58 (16–79) | 59 (16–79) | 56 (16–79) | 0.004 |
Sex, n (%) | ||||
 Female | 149 (44.3) | 96 (51.6) | 53 (35.3) | 0.003 |
 Male | 187 (55.7) | 90 (48.4) | 97 (64.7) |  |
KPS, n (%) | ||||
  ≤ 70 | 172 (51.2) | 104 (55.9) | 68 (45.3) | 0.156 |
 80 | 82 (24.4) | 41 (22) | 41 (27.3) |  |
  ≥ 90 | 82 (24.4) | 41 (22) | 41 (27.3) |  |
Extent of resection, n (%) | ||||
 Total | 206 (61.3) | 109 (58.6) | 97 (64.7) | 0.009 |
 Subtotal/Partial | 108 (32.1) | 70 (37.6) | 38 (25.3) |  |
 Biopsy | 22 (6.5) | 7 (3.8) | 15 (10) |  |
IDH1 mutation, n (%) | ||||
 No | 250 (74.4) | 117 (62.9) | 133 (88.7) | < 0.001 |
 Yes | 18 (5.4) | 6 (3.2) | 12 (8) |  |
 unknown | 68 (20.2) | 63 (33.9) | 5 (3.3) |  |
MGMT, n (%) | ||||
 Unmethylated | 212 (63.1) | 115 (61.8) | 97 (64.7) | 0.592 |
 Methylated | 124 (36.9) | 71 (38.2) | 53 (35.3) |  |
Subventriclular zone, n (%) | ||||
 Uninvolved | 206 (61.3) | 122 (65.6) | 84 (56) | 0.073 |
 Involved | 130 (38.7) | 64 (34.4) | 66 (44) |  |
PTV1 volume, cm3, median (range) | 403 (71–1080) | 422 (74–1080) | 375 (71–1041) | <.001 |
PTV2 volume, cm3, median (range) | 113 (6–475) | 119 (12–475) | 103 (6–468) | 0.002 |
Total dose, Gy, median (range) | 60 (41–72.5) | 60 (54–70) | 60 (41–72.5) | 0.073 |
No. of fractionation, median (range) | 30 (15–35) | 30 (23–35) | 30 (15–33) | <.001 |
Baseline TLC, /μL, median (range) | 1370 (300–3740) | 1365 (300–3740) | 1385 (410–3640) | 0.648 |
Baseline TLC, /μL, n (%) | ||||
  < 1000 | 81 (24.1) | 45 (24.2) | 36 (24) | 0.893 |
  ≥ 1000 | 255 (75.9) | 141 (75.8) | 114 (76) |  |
The cumulative dose of temozolomidea, mg/m2, median (range) | 3588 (722–6267) | 3497 (856–6267) | 3684 (722–5599) | 0.117 |